U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Reuters2024-12-30

U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Dec 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.

HIGHLIGHTS

* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating

* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating

* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110

Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order

* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating

* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating

* BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3

* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97

* Emergent Biosolutions EBS.N: H.C. Wainwright initiates coverage with buy rating; PT $15

* Exelixis Inc EXEL.O: RBC raises target price to $38 from $34

* Insulet Corp PODD.O: BTIG raises target price to $300 from $270

* Metavia Inc MTVA.O: H.C. Wainwright initiates coverage with buy rating; PT $12

* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2495354814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-30 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495354814","market":"us","top_or_hot":-1,"title":"U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent </title></head><body><p><span>Dec 30 (Reuters)</span><span> - </span>Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday. </p><p> <span>HIGHLIGHTS   </span> </p><table><tbody><tr><td><p><span>* Arcutis Biotherapeutics <span>ARQT.O</span>: H<a href=\"https://laohu8.com/S/02403\">.C</a>. Wainwright initiates coverage with buy rating</span></p></td></tr><tr><td><p><span>* Artiva Biotherapeutics <span>ARTV.O</span>: H.C. Wainwright initiates coverage with buy rating </span></p></td></tr><tr><td><p><span>* Nuvalent Inc <span>NUVL.O</span>: H.C. Wainwright initiates coverage with buy rating and PT $110</span></p></td></tr></tbody></table><p>Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order</p><table><tbody><tr><td><p><span>* Arcutis Biotherapeutics <span>ARQT.O</span>: H.C. Wainwright initiates coverage with buy rating</span></p></td></tr><tr><td><p><span>* Artiva Biotherapeutics <span>ARTV.O</span>: H.C. Wainwright initiates coverage with buy rating </span></p></td></tr><tr><td><p><span>* <a href=\"https://laohu8.com/S/BBAI\">BigBear.ai Holdings</a> Inc <span>BBAI.N</span>: H.C. Wainwright raises PT to $7 from $3</span></p></td></tr><tr><td><p><span>* Boston Scientific Corp <span>BSX.N</span>: BTIG raises target price to $101 from $97 </span></p></td></tr><tr><td><p><span>* <a href=\"https://laohu8.com/S/EBS\">Emergent Biosolutions</a> <span>EBS.N</span>: H.C. Wainwright initiates coverage with buy rating; PT $15</span></p></td></tr><tr><td><p><span>* Exelixis Inc <span>EXEL.O</span>: RBC raises target price to $38 from $34</span></p></td></tr><tr><td><p><span>* Insulet Corp <span>PODD.O</span>: BTIG raises target price to $300 from $270</span></p></td></tr><tr><td><p><span>* Metavia Inc <span>MTVA.O</span>: H.C. Wainwright initiates coverage with buy rating; PT $12</span></p></td></tr><tr><td><p><span>* Nuvalent Inc <span>NUVL.O</span>: H.C. Wainwright initiates coverage with buy rating and PT $110</span></p></td></tr></tbody></table><p> (Compiled by Bengaluru Newsroom)</p><p> ((Diaries@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-30 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nL4N3NV0FC:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent Dec 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nL4N3NV0FC:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nL4N3NV0FC:1","article_id":"2495354814","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495354814","pubTimestamp":1735558819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent Dec 30  - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.  HIGHLIGHTS    * Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97 * Emerg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4551":"寇图资本持仓","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BBAI":"BigBear.ai Holdings","BK4581":"高盛持仓","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","MTVA":"MetaVia Inc","LU0882574055.USD":"富达全球健康医疗A ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","ARTV":"Artiva Biotherapeutics, Inc.","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4539":"次新股","ARQT":"Arcutis Biotherapeutics Inc.","BK4583":"猴痘概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","PODD":"银休特","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BSX":"波士顿科学","EXEL":"伊克力西斯","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","BK4139":"生物科技","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","EBS":"Emergent Biosolutions","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4587":"ChatGPT概念","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","NUVL":"Nuvalent, Inc.","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","BK4082":"医疗保健设备","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC"},"translate_title":"美国研究综述-Arcutis Biotherapeutics、Artiva Biotherapeutics、Nuvalent","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTV":0.9,"PODD":0.9,"NUVL":0.9,"MTVA":0.9,"EXEL":0.9,"EBS":0.9,"BSX":0.9,"ARQT":0.9,"BBAI":0.9},"content_text":"U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent Dec 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.  HIGHLIGHTS    * Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97 * Emergent Biosolutions EBS.N: H.C. Wainwright initiates coverage with buy rating; PT $15* Exelixis Inc EXEL.O: RBC raises target price to $38 from $34* Insulet Corp PODD.O: BTIG raises target price to $300 from $270* Metavia Inc MTVA.O: H.C. Wainwright initiates coverage with buy rating; PT $12* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110 (Compiled by Bengaluru Newsroom) ((Diaries@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2495354814"}